Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
Cumulative follow-up with HX575 epoetin alfa to prospectively monitor the incidence of
relevant drug-related adverse events and EPO-related lack of efficacy among Chronic Kidney
Disease (CKD) subjects receiving HX575 epoetin alfa i.v.